Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.
[EN] NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE PROLYLCARBOXYPEPTIDASE
申请人:MERCK SHARP & DOHME
公开号:WO2011146300A1
公开(公告)日:2011-11-24
Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.